Compare RC & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RC | ASMB |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | 442 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.3M | 440.0M |
| IPO Year | N/A | 2010 |
| Metric | RC | ASMB |
|---|---|---|
| Price | $1.62 | $29.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.81 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 1.7M | 71.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $67.36 | $235.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $9.68 |
| 52 Week High | $4.75 | $39.71 |
| Indicator | RC | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 53.69 |
| Support Level | $1.53 | $29.31 |
| Resistance Level | $2.15 | $30.54 |
| Average True Range (ATR) | 0.07 | 1.36 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 86.21 | 70.45 |
Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.